Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 15 | 2023 | 13381 | 0.890 |
Why?
|
| Radiosurgery | 7 | 2022 | 1342 | 0.880 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2016 | 491 | 0.680 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2022 | 173 | 0.660 |
Why?
|
| Thoracic Wall | 1 | 2020 | 202 | 0.620 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2023 | 5314 | 0.600 |
Why?
|
| Radiation Oncology | 1 | 2024 | 563 | 0.580 |
Why?
|
| Androgen Antagonists | 2 | 2016 | 1410 | 0.550 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2018 | 2297 | 0.550 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2018 | 185 | 0.540 |
Why?
|
| Pancreatic Neoplasms | 4 | 2023 | 5368 | 0.530 |
Why?
|
| Laparotomy | 1 | 2018 | 457 | 0.510 |
Why?
|
| Intraoperative Care | 2 | 2019 | 767 | 0.500 |
Why?
|
| Adenocarcinoma | 3 | 2023 | 6345 | 0.490 |
Why?
|
| Liver Neoplasms | 3 | 2018 | 4317 | 0.440 |
Why?
|
| Papillomaviridae | 2 | 2016 | 1119 | 0.400 |
Why?
|
| Education, Medical | 1 | 2024 | 1725 | 0.400 |
Why?
|
| Neoadjuvant Therapy | 5 | 2021 | 2828 | 0.360 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2019 | 1728 | 0.350 |
Why?
|
| Lung Diseases, Interstitial | 3 | 2023 | 918 | 0.340 |
Why?
|
| Thrombosis | 1 | 2023 | 2942 | 0.330 |
Why?
|
| Neoplasm Staging | 7 | 2021 | 11120 | 0.330 |
Why?
|
| Prostatic Neoplasms | 3 | 2016 | 11122 | 0.300 |
Why?
|
| Immunotherapy | 2 | 2019 | 4652 | 0.260 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 5841 | 0.240 |
Why?
|
| Lymph Nodes | 1 | 2015 | 3465 | 0.220 |
Why?
|
| Mesenteric Veins | 1 | 2023 | 86 | 0.210 |
Why?
|
| Papillomavirus Infections | 1 | 2015 | 1613 | 0.210 |
Why?
|
| Radiotherapy | 2 | 2019 | 1498 | 0.210 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2020 | 1660 | 0.200 |
Why?
|
| Competency-Based Education | 1 | 2024 | 222 | 0.200 |
Why?
|
| Brachytherapy | 2 | 2022 | 1223 | 0.190 |
Why?
|
| Portal Vein | 1 | 2023 | 431 | 0.180 |
Why?
|
| SEER Program | 2 | 2016 | 1450 | 0.180 |
Why?
|
| Eye Neoplasms | 1 | 2022 | 307 | 0.180 |
Why?
|
| Fluorouracil | 3 | 2021 | 1642 | 0.170 |
Why?
|
| Lung | 5 | 2023 | 10002 | 0.170 |
Why?
|
| Combined Modality Therapy | 4 | 2019 | 8527 | 0.170 |
Why?
|
| Esophageal Neoplasms | 2 | 2021 | 1654 | 0.170 |
Why?
|
| Stomach Neoplasms | 2 | 2021 | 1459 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 4024 | 0.160 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 638 | 0.160 |
Why?
|
| Radiobiology | 1 | 2019 | 90 | 0.160 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 13642 | 0.160 |
Why?
|
| Lymphatic Metastasis | 2 | 2018 | 2915 | 0.160 |
Why?
|
| Pulmonary Fibrosis | 1 | 2023 | 505 | 0.160 |
Why?
|
| Humans | 39 | 2024 | 761596 | 0.160 |
Why?
|
| Edema | 1 | 2022 | 766 | 0.160 |
Why?
|
| Early Detection of Cancer | 3 | 2022 | 3201 | 0.150 |
Why?
|
| Bicarbonates | 1 | 2019 | 292 | 0.150 |
Why?
|
| Cryosurgery | 1 | 2023 | 474 | 0.150 |
Why?
|
| Aged | 18 | 2023 | 169310 | 0.150 |
Why?
|
| Retrospective Studies | 11 | 2023 | 80647 | 0.140 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2018 | 882 | 0.140 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2022 | 515 | 0.130 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2019 | 509 | 0.130 |
Why?
|
| ras Proteins | 2 | 2011 | 1054 | 0.130 |
Why?
|
| Esophagogastric Junction | 1 | 2018 | 347 | 0.130 |
Why?
|
| Survival Analysis | 2 | 2018 | 10090 | 0.130 |
Why?
|
| Aged, 80 and over | 11 | 2021 | 58984 | 0.130 |
Why?
|
| Photons | 1 | 2019 | 589 | 0.120 |
Why?
|
| Pancreatectomy | 1 | 2019 | 811 | 0.120 |
Why?
|
| Thorax | 1 | 2018 | 555 | 0.120 |
Why?
|
| Dyspnea | 1 | 2022 | 1347 | 0.120 |
Why?
|
| Prognosis | 6 | 2019 | 29629 | 0.120 |
Why?
|
| Radiotherapy, Conformal | 1 | 2018 | 548 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 6484 | 0.110 |
Why?
|
| Immune System | 1 | 2019 | 796 | 0.110 |
Why?
|
| Deoxycytidine | 1 | 2018 | 877 | 0.110 |
Why?
|
| Risk | 2 | 2016 | 9610 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2021 | 11742 | 0.110 |
Why?
|
| Radiotherapy Dosage | 4 | 2022 | 2898 | 0.110 |
Why?
|
| Middle Aged | 17 | 2022 | 220921 | 0.110 |
Why?
|
| Radiation Dosage | 1 | 2021 | 1958 | 0.110 |
Why?
|
| Airway Obstruction | 1 | 2018 | 661 | 0.100 |
Why?
|
| Cysts | 1 | 2018 | 681 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 1784 | 0.100 |
Why?
|
| 3' Untranslated Regions | 2 | 2011 | 519 | 0.100 |
Why?
|
| Radiation Injuries | 1 | 2019 | 1189 | 0.100 |
Why?
|
| Male | 18 | 2022 | 360846 | 0.100 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2022 | 2118 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 39106 | 0.090 |
Why?
|
| Pneumonia | 1 | 2023 | 2143 | 0.090 |
Why?
|
| Cohort Studies | 5 | 2023 | 41495 | 0.090 |
Why?
|
| Lymphocytes | 1 | 2019 | 2612 | 0.090 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 1265 | 0.090 |
Why?
|
| Prospective Studies | 6 | 2022 | 54423 | 0.090 |
Why?
|
| Curriculum | 1 | 2024 | 3743 | 0.090 |
Why?
|
| Female | 18 | 2023 | 392705 | 0.090 |
Why?
|
| Cholangiocarcinoma | 1 | 2015 | 552 | 0.090 |
Why?
|
| Bile Duct Neoplasms | 1 | 2015 | 605 | 0.080 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 4915 | 0.080 |
Why?
|
| Treatment Outcome | 6 | 2021 | 64685 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2011 | 4514 | 0.080 |
Why?
|
| Leucovorin | 2 | 2021 | 643 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2018 | 2425 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2021 | 9280 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2022 | 12973 | 0.070 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2011 | 487 | 0.070 |
Why?
|
| Survival Rate | 2 | 2019 | 12723 | 0.070 |
Why?
|
| Neoplasms | 3 | 2021 | 22173 | 0.070 |
Why?
|
| Protons | 2 | 2022 | 1116 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2022 | 20568 | 0.070 |
Why?
|
| Prostate-Specific Antigen | 1 | 2016 | 2469 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 10766 | 0.070 |
Why?
|
| Neutrophils | 1 | 2019 | 3767 | 0.070 |
Why?
|
| Mass Screening | 1 | 2021 | 5429 | 0.060 |
Why?
|
| Cause of Death | 1 | 2015 | 3683 | 0.060 |
Why?
|
| Melanoma | 1 | 2022 | 5709 | 0.060 |
Why?
|
| Incidence | 1 | 2022 | 21355 | 0.050 |
Why?
|
| Adult | 7 | 2022 | 221210 | 0.050 |
Why?
|
| Hypertension | 1 | 2022 | 8540 | 0.050 |
Why?
|
| Contrast Media | 1 | 2015 | 5307 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 2894 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 12463 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 21019 | 0.040 |
Why?
|
| Inflammation | 1 | 2019 | 10774 | 0.040 |
Why?
|
| Risk Factors | 2 | 2018 | 74213 | 0.040 |
Why?
|
| Troponin | 1 | 2022 | 502 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 15266 | 0.040 |
Why?
|
| Ohio | 1 | 2019 | 322 | 0.040 |
Why?
|
| Neck | 1 | 2022 | 734 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 2019 | 478 | 0.040 |
Why?
|
| Fibrosis | 1 | 2022 | 2049 | 0.030 |
Why?
|
| Esophagus | 1 | 2021 | 1033 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 4878 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2011 | 1745 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 1379 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2014 | 23996 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 15936 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2018 | 1302 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2018 | 1036 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2022 | 5112 | 0.020 |
Why?
|
| Echocardiography | 1 | 2022 | 4989 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 6815 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2022 | 3879 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2015 | 1892 | 0.020 |
Why?
|
| Calcium | 1 | 2022 | 5722 | 0.020 |
Why?
|
| Carboplatin | 1 | 2011 | 794 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2022 | 5496 | 0.020 |
Why?
|
| Young Adult | 1 | 2015 | 59260 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2021 | 8633 | 0.020 |
Why?
|
| Genes, BRCA1 | 1 | 2011 | 764 | 0.020 |
Why?
|
| BRCA2 Protein | 1 | 2011 | 805 | 0.020 |
Why?
|
| Adolescent | 1 | 2015 | 88326 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2811 | 0.020 |
Why?
|
| Animals | 1 | 2018 | 168475 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2011 | 1129 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 3878 | 0.020 |
Why?
|
| BRCA1 Protein | 1 | 2011 | 1158 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 8002 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2011 | 1732 | 0.010 |
Why?
|
| RNA Interference | 1 | 2011 | 2832 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 2209 | 0.010 |
Why?
|
| Cell Survival | 1 | 2011 | 5791 | 0.010 |
Why?
|
| Receptor, erbB-2 | 1 | 2011 | 2557 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 12059 | 0.010 |
Why?
|
| Genotype | 1 | 2011 | 12990 | 0.010 |
Why?
|
| Mutation | 2 | 2011 | 30053 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2011 | 5305 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 16990 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 22176 | 0.010 |
Why?
|
| United States | 1 | 2021 | 72340 | 0.010 |
Why?
|
Concepts
(163)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(87)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_